Porter Paisley Vinson

22q11.2 Deletion Syndrome - Global Market Insights, Epidemiology and Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, December 17, 2021
Genetics, Pharmaceutical, Health, Epidemiology, Lists of diseases, 1p36 deletion syndrome, Microdeletion syndrome, Total, SWOT, Gaps, SME, Behavior, Clinical trial, Diagnosis, Commonwealth Center for Children and Adolescents, DiGeorge syndrome, USD, Growth–share matrix, Porter Paisley Vinson, B cell, ADHD, CAGR, Lists of people executed in the United States, Adolescence, Child psychopathology, Patient, PESTLE, Quality of life, Profile, Immune system, Prevalence, Parent, Sumitomo Dainippon Pharma, Bone marrow, Schizophrenia, CBD, Attention deficit hyperactivity disorder, Anxiety disorder, Psychosis, INSPIRE, Competitive intelligence, Skin, News, Competition, Heart, View, Residential care, Pharmaceutical industry, Dentistry, Marketing, Autism, Cannabidiol, Infant, Jean-François Zygel

The 22q11.2 deletion syndrome epidemiology division provides the insights about historical and current 22q11.2 deletion syndrome patient pool and forecasted trend for each seven major countries.

Key Points: 
  • The 22q11.2 deletion syndrome epidemiology division provides the insights about historical and current 22q11.2 deletion syndrome patient pool and forecasted trend for each seven major countries.
  • The disease epidemiology covered in the report provides historical as well as forecasted 22q11.2 deletion syndrome epidemiology [segmented as Total Prevalent Cases of 22q11.2 deletion syndrome, Total Diagnosed Prevalent Cases of 22q11.2 deletion syndrome, Total diagnosed prevalent cases of 22q11.2 deletion syndrome by age group, Total diagnosed prevalent cases of 22q11.2 deletion syndrome with Behavioral and Psychiatric phenotypes, and Total treated cases of 22q11.2 deletion syndrome with behavioral and psychiatric phenotypes scenario of 22q11.2 deletion syndrome in the 7MM covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2018 to 2030.
  • Drug chapter segment of the 22q11.2 deletion syndrome report encloses the detailed analysis of 22q11.2 deletion syndrome pipeline drugs.
  • The 22q11.2 deletion syndrome market size in the 7MM is expected to change during the forecast period (2021-2030), at a CAGR of 41.9%.